<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS202434</article-id><article-id pub-id-type="doi">10.1101/2024.12.28.630583</article-id><article-id pub-id-type="archive">PPR960929</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Chromosome end protection by RAP1-mediated inhibition of DNA-PK</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Eickhoff</surname><given-names>Patrik</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sonmez</surname><given-names>Ceylan</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Fisher</surname><given-names>Charlotte E.L.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Inian</surname><given-names>Oviya</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Roumeliotis</surname><given-names>Theodoros I.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>dello Stritto</surname><given-names>Angela</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Mansfeld</surname><given-names>Jörg</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Choudhary</surname><given-names>Jyoti S.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Guettler</surname><given-names>Sebastian</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lottersberger</surname><given-names>Francisca</given-names></name><xref ref-type="aff" rid="A5">5</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Douglas</surname><given-names>Max E.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><aff id="A1"><label>1</label>Telomere Biology Laboratory, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/043jzw605</institution-id><institution>The Institute of Cancer Research</institution></institution-wrap>, <addr-line>237 Fulham Road</addr-line>, <city>London</city><postal-code>SW3 6JB</postal-code></aff><aff id="A2"><label>2</label>Structural Biology of Cell Signalling, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/043jzw605</institution-id><institution>The Institute of Cancer Research</institution></institution-wrap>, <addr-line>237 Fulham Road</addr-line>, <city>London</city><postal-code>SW3 6JB</postal-code></aff><aff id="A3"><label>3</label>Functional Proteomics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/043jzw605</institution-id><institution>The Institute of Cancer Research</institution></institution-wrap>, <addr-line>237 Fulham Road</addr-line>, <city>London</city><postal-code>SW3 6JB</postal-code></aff><aff id="A4"><label>4</label>Post-translational Modifications and Cell Proliferation, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/043jzw605</institution-id><institution>The Institute of Cancer Research</institution></institution-wrap>, <addr-line>237 Fulham Road</addr-line>, <city>London</city><postal-code>SW3 6JB</postal-code></aff><aff id="A5"><label>5</label>Department of Biomedical and Clinical Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05ynxx418</institution-id><institution>Linköping University</institution></institution-wrap>, <city>Linköping</city>, <postal-code>58185</postal-code>, <country country="SE">Sweden</country></aff></contrib-group><author-notes><corresp id="CR1">
<label>*</label>Correspondence and requests for materials should be addressed to M.E.D and F.L., Correspondence: <email>max.douglas@icr.ac.uk</email> (Tel: +44 (0) 207 153 5061) and <email>francisca.lottersberger@liu.se</email> (Tel: +46 13286881)</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>17</day><month>01</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>28</day><month>12</month><year>2024</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">During classical non-homologous end joining (cNHEJ), DNA-dependent protein kinase (DNA-PK) encapsulates free DNA ends, forming a recruitment platform for downstream end-joining factors including Ligase 4 (LIG4)<sup><xref ref-type="bibr" rid="R1">1</xref></sup>. DNA-PK can also bind telomeres and regulate their resection<sup><xref ref-type="bibr" rid="R2">2</xref>-<xref ref-type="bibr" rid="R4">4</xref></sup>, but does not initiate cNHEJ at this position. How the end joining process is regulated in this context-specific manner is currently unclear. Here we show that the shelterin components TRF2 and RAP1 form a complex with DNA-PK that directly represses its end joining function at telomeres. Biochemical experiments and cryo-electron microscopy reveal that when bound to TRF2, RAP1 establishes a network of interactions with KU and DNA that prevents DNA-PK from recruiting LIG4. In mouse and human cells, RAP1 is redundant with the Apollo nuclease in repressing cNHEJ at chromosome ends, demonstrating that the inhibition of DNA-PK prevents telomere fusions in parallel with overhang-dependent mechanisms. Our experiments show that the end joining function of DNA-PK is directly and specifically repressed at telomeres, establishing a molecular mechanism for how individual linear chromosomes are maintained in mammalian cells.</p></abstract></article-meta></front><body><p id="P2">Mammalian telomeres are protected from cNHEJ by the shelterin subunit TRF2, which is proposed to hide the chromosome end from DNA repair factors by forming a lariat structure referred to as a t-loop<sup><xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R6">6</xref></sup>. T-loop assembly requires a terminal 3’ overhang<sup><xref ref-type="bibr" rid="R7">7</xref></sup>, which at blunt telomeres resulting from leading strand DNA replication, is formed via a 5’ resection step mediated by Apollo exonuclease<sup><xref ref-type="bibr" rid="R8">8</xref>-<xref ref-type="bibr" rid="R12">12</xref></sup>. Surprisingly, DNA-PK is required for this resection step, but is unable to activate cNHEJ even after Apollo deletion<sup><xref ref-type="bibr" rid="R13">13</xref></sup>, suggesting a mechanism is in place to directly block the end joining process at telomeres. We hypothesised this mechanism may involve the conserved shelterin subunit RAP1. In budding yeast, Rap1 binds directly to telomeres and protects them from cNHEJ<sup><xref ref-type="bibr" rid="R14">14</xref></sup>. However, in mammalian cells, RAP1 is recruited via TRF2 and its role in end protection remains elusive<sup><xref ref-type="bibr" rid="R15">15</xref>-<xref ref-type="bibr" rid="R19">19</xref></sup>.</p><p id="P3">To examine this idea, we employed telomere-fluorescence in situ hybridisation (FISH) to measure chromosome fusions in conditional Apollo knockout (KO) mouse embryonic fibroblasts (MEFs) with or without RAP1 (<xref ref-type="supplementary-material" rid="SD1">Fig. S1a</xref>). In agreement with previous studies, Apollo-deleted MEFs showed some chromatid fusions that were LIG4-independent and so not caused by cNHEJ (<xref ref-type="fig" rid="F1">Figs. 1a-c</xref>, compare –sgRap1, ±Cre)<sup><xref ref-type="bibr" rid="R13">13</xref></sup>. No fusions were observed upon Crispr-mediated deletion of RAP1 in Apollo proficient MEFs, also consistent with previous work<sup><xref ref-type="bibr" rid="R19">19</xref>-<xref ref-type="bibr" rid="R21">21</xref></sup> (<xref ref-type="fig" rid="F1">Figs. 1a-c</xref>, compare ±sgRap1, –Cre). However, when RAP1 and Apollo were deleted together, approximately 15 % of telomeres per metaphase were engaged in LIG4-dependent chromosome-type fusions (<xref ref-type="fig" rid="F1">Figs. 1a and c</xref>, +sgRap1, +Cre). A similar effect was induced by mutating the binding sites for Apollo and RAP1 on TRF2, and the resulting fusions were prevented by deleting the iDDR (<xref ref-type="supplementary-material" rid="SD1">Fig. S1b-d</xref>), which restores telomeric overhangs in the absence of Apollo<sup><xref ref-type="bibr" rid="R13">13</xref></sup>. The data above strongly suggests that 3’ overhangs and RAP1 can each protect mouse telomeres from cNHEJ. To test whether this is also the case for human telomeres, we repeated the analysis in non-transformed human cells. Unlike in cancer cell lines<sup><xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R23">23</xref></sup> telomere fusions were not induced in p53-/-RPE-1 cells lacking only Apollo (<xref ref-type="fig" rid="F1">Figs. 1d, e</xref> and <xref ref-type="supplementary-material" rid="SD1">S1g</xref>). However, consistent with the data above, 20-30 % of telomeres fused in a DNA-PK-dependent manner when RAP1 was also removed (<xref ref-type="fig" rid="F1">Figs. 1d, e</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S1e-h</xref>). A proportion of these fusions involved only one telomere per chromosome end and in line with the established role of Apollo, these telomeres had exclusively been replicated as the leading strand (<xref ref-type="supplementary-material" rid="SD1">Fig. S1g and i</xref>). We conclude that in mouse and human cells, telomeres are protected from cNHEJ by two equally effective and parallel pathways: 3’ overhangs and the presence of RAP1.</p><p id="P4">We focused out attention on the protective role of RAP1. As shelterin coprecipitates with KU and DNA-PKcs in cell extracts<sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R24">24</xref>-<xref ref-type="bibr" rid="R27">27</xref></sup>, we considered whether RAP1 might prevent cNHEJ by binding directly to DNA-PK. To test this idea, we used DNase I footprinting to examine the position of purified shelterin and DNA-PK on a blunt-ended telomeric template (<xref ref-type="fig" rid="F2">Fig. 2a</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S2a</xref>). DNA-PK protected 32 bp from the telomere end, consistent with the assembly of a terminally positioned complex<sup><xref ref-type="bibr" rid="R28">28</xref></sup> (<xref ref-type="fig" rid="F2">Fig. 2b</xref>, compare lanes 1 and 2). Addition of shelterin reduced the overall efficiency of DNase I cleavage (compare lanes 1 and 6). However, a novel footprint of precisely 10 bp not observed with shelterin alone was also visible directly next to DNA-PK (‘shelterin’ region). A complex of RAP1 and TRF2<sup><xref ref-type="bibr" rid="R29">29</xref></sup>, but not each component alone was sufficient for this effect (<xref ref-type="fig" rid="F2">Figs. 2c-e</xref>), which was specific to telomeric DNA (<xref ref-type="fig" rid="F2">Fig. 2f</xref>) and observed over a range of protein concentrations (<xref ref-type="supplementary-material" rid="SD1">Fig. S2b</xref>). <xref ref-type="supplementary-material" rid="SD1">Fig. S2c</xref> shows the same footprint next to DNA-PK was also observed in the presence of a 3’ overhang (lanes 6 and 8), but only in the absence of POT1/TPP1, which otherwise prevented DNA-PK assembly (lanes 6 and 7).</p><p id="P5">The data above suggests that DNA-PK bound to telomeric ends can form a sequence-specific complex with TRF2 and RAP1. To examine the architecture of this complex, we determined which domains were required for the DNA-PK-proximal footprint (<xref ref-type="fig" rid="F3">Fig. 3a</xref>, <xref ref-type="supplementary-material" rid="SD1">Figs. S2d and e</xref>). Binding of RAP1 to TRF2 via the RCT/RBM interface<sup><xref ref-type="bibr" rid="R30">30</xref></sup>, and binding of TRF2 to DNA via the myb- but not the basic domain was necessary for the extended footprint, suggesting a model in which RAP1 is recruited to DNA by TRF2 for the complex to form (<xref ref-type="fig" rid="F3">Figs. 3b and c</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S2f</xref>). We tested whether this is the primary function of TRF2 in the assay by fusing RAP1 to the DNA-binding domain of fission yeast Teb1, which recognises TTAGGG repeats<sup><xref ref-type="bibr" rid="R15">15</xref></sup>. In the presence of DNA-PK, the Teb1:RAP1 fusion protein generated a 10 bp footprint indistinguishable from that of RAP1 in complex with TRF2 and prevented by cleavage of the Teb1:RAP1 linker (<xref ref-type="fig" rid="F3">Fig. 3d</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S2g and h</xref>). Thus, the role of TRF2 in forming the complex is to recruit RAP1 to DNA, and the extended footprint is caused by RAP1, not TRF2.</p><p id="P6">As RAP1 has been proposed to bind KU in cell extracts<sup><xref ref-type="bibr" rid="R25">25</xref>,<xref ref-type="bibr" rid="R26">26</xref></sup>, we examined whether purified RAP1 and KU could bind one another in pulldown assays but did not detect an interaction. However, when RAP1 and KU were mixed in the presence of an amine-specific crosslinker and DNA, we observed a crosslinked species on silver-stained polyacrylamide gels that contained RAP1 and KU as demonstrated by immuno-blotting, suggesting RAP1 mediates a weak interaction with KU (<xref ref-type="fig" rid="F3">Fig. 3e</xref>). Deleting either the RAP1 BRCT- or myb domains disrupted this binding (<xref ref-type="fig" rid="F3">Fig. 3e</xref>) and prevented the extended signal in a footprinting assay (<xref ref-type="fig" rid="F3">Fig. 3f</xref>, compare lanes 3-5). To test whether the BRCT domain could be substituted for a different DNA-PK-binding peptide, we fused RAP1ΔBRCT to the first BRCT domain of LIG4, which recognises KU70<sup><xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R32">32</xref></sup>. <xref ref-type="fig" rid="F3">Figure 3g</xref> shows that adding the LIG4 BRCT domain to RAP1ΔBRCT rescued the 10 bp footprint next to DNA-PK (compare lanes 2-4), confirming that the necessary function of the RAP1 BRCT domain in forming the complex is recognition of KU.</p><p id="P7">While it is possible that one or other of these regions directly protects the 10 bp next to DNA-PK (see below), these data reveal that three molecular interfaces are required for TRF2 and RAP1 to form a complex with DNA-PK: binding of TRF2 to DNA, binding of TRF2 to RAP1, and binding of RAP1 to KU. The requirement for TRF2 to bind DNA explains why the extended footprint is not formed at non-telomeric ends (<xref ref-type="fig" rid="F2">Fig. 2f</xref>), which do not contain a TRF2 binding site.</p><p id="P8">To determine how this complex might inhibit cNHEJ at telomeres (<xref ref-type="fig" rid="F1">figure 1</xref>), we used cryo-electron microscopy (cryo-EM) to examine the structure of TRF2, RAP1 and DNA-PK on telomeric DNA. Consecutive rounds of classification followed by focussed refinement yielded an overall structure at 3.58 Å (<xref ref-type="fig" rid="F4">Fig. 4a</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S3</xref> and <xref ref-type="supplementary-material" rid="SD2">Supplementary Video 1</xref>). Our map did not contain TRF2, consistent with the notion that its primary role in the complex is to recruit RAP1 to DNA rather than stably bind DNA-PK. The conformation of DNA-PKcs was consistent with previous structures of the unphosphorylated enzyme<sup><xref ref-type="bibr" rid="R33">33</xref></sup> (<xref ref-type="supplementary-material" rid="SD1">Fig. S4</xref>).</p><p id="P9">Three additional regions of density were observed beyond the core DNA-PK complex: the first sits on the DNA as it enters KU and was modelled as the KU70 SAP domain, visualised here on DNA for the first time (<xref ref-type="fig" rid="F4">Fig. 4a and b</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S5a</xref>). The SAP domain, which remains functionally enigmatic, is positioned on the minor groove with K575, K595 and K596, which have been suggested to bind DNA<sup><xref ref-type="bibr" rid="R34">34</xref></sup>, coordinating the phosphate backbone (<xref ref-type="supplementary-material" rid="SD1">Fig. S5a</xref>). The second region engages the neighbouring 10 bp that are protected by RAP1 in our footprinting assays and was modelled as the RAP1 myb domain (<xref ref-type="fig" rid="F4">Figs. 4a and b</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S5b</xref>). The myb adopts a canonical homeodomain arrangement with the recognition helix inserted into the major groove and a conserved N-terminal arm<sup><xref ref-type="bibr" rid="R35">35</xref></sup> formed by R133 reaching into the minor groove bound by the KU70 SAP (<xref ref-type="fig" rid="F4">Fig. 4b</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S5b-d</xref>). Chemical crosslinking mass spectrometry confirms the proximity of the myb and SAP regions (<xref ref-type="supplementary-material" rid="SD1">Fig. S5e and f</xref>). This density is surprising because human RAP1 does not appreciably bind DNA in isolation due to a lack of surface-exposed positive charge<sup><xref ref-type="bibr" rid="R29">29</xref>,<xref ref-type="bibr" rid="R36">36</xref>,<xref ref-type="bibr" rid="R37">37</xref></sup>. Our structure suggests DNA-PK complements this deficit by anchoring the myb domain close to DNA through a neighbouring loop bound to the side of KU80 (<xref ref-type="supplementary-material" rid="SD1">Fig. S5g</xref>). The KU70 SAP is proposed to bind other homeodomain proteins<sup><xref ref-type="bibr" rid="R38">38</xref></sup> and additional contacts with RAP1 may also be in place but are not resolved in our structure. A single point mutation in the N-terminal arm (R133E) blocked the footprint next to DNA-PK (<xref ref-type="fig" rid="F4">Fig. 4e</xref>), consistent with the myb:DNA interaction protecting this region.</p><p id="P10">The third region sits on the KU70 vWA domain and was modelled as the BRCT domain of RAP1 (<xref ref-type="fig" rid="F4">Figs. 4a and c</xref>), positioning a conserved basic patch on RAP1 next to an acidic patch on KU (<xref ref-type="fig" rid="F4">Fig. 4d</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S6a</xref>). Consistent with our structure, charge reversal mutations in these regions prevented the extended signal in a footprinting assay (<xref ref-type="fig" rid="F4">Fig. 4f and g</xref>, RAP1 KR/DE and KU DE/KR) and crosslinking of RAP1 to KU (<xref ref-type="supplementary-material" rid="SD1">Fig. S6c</xref> compare lanes 7, 9 and 11). Remarkably, overlaying the RAP1 BRCT domain with the LIG4 BRCT domain bound to KU<sup><xref ref-type="bibr" rid="R32">32</xref></sup> shows that RAP1 at this position directly occludes the binding site for LIG4 (<xref ref-type="fig" rid="F4">Fig. 4h</xref>). These data suggest that by forming a complex with DNA-PK, TRF2 and RAP1 may prevent cNHEJ by simply blocking Ligase 4 recruitment.</p><p id="P11">To test this idea, we developed a pulldown assay in which purified KU was immunoprecipitated after incubation with purified DNA-PKcs, purified XRCC4/LIG4 and a short DNA template (<xref ref-type="fig" rid="F5">Fig. 5a</xref>). DNA-PKcs associated with KU in a DNA-dependent manner, consistent with the assembly of DNA-PK at a DNA end (<xref ref-type="supplementary-material" rid="SD1">Fig. S7a</xref>). XRCC4/LIG4 recruitment was sensitive to mutations in the acidic patch on KU that is required to bind RAP1 and known to bind LIG4<sup><xref ref-type="bibr" rid="R32">32</xref></sup> (<xref ref-type="supplementary-material" rid="SD1">Fig. S7a</xref>, compare lanes 7 and 8). While TRF2 or RAP1 had a negligible effect on the assay individually, recruitment of XRCC4/LIG4 was blocked when they were added together, even when XRCC4/LIG4 was preincubated with DNA-PK and present in large excess (<xref ref-type="fig" rid="F5">Fig. 5b</xref> and <xref ref-type="supplementary-material" rid="SD1">Figs. S7b and c</xref>). To test whether the ability of TRF2/RAP1 to block LIG4 recruitment required binding to DNA-PK, we repeated the experiment with RAP1 ΔBRCT or KR/DE, which are unable to bind KU (<xref ref-type="fig" rid="F4">Figure 4</xref>). Inhibition of LIG4 recruitment was not observed under these conditions but could be restored by fusing the N-terminal BRCT domain of LIG4 onto the N-terminus of RAP1ΔBRCT (<xref ref-type="fig" rid="F5">Fig. 5c</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S7d</xref>). <xref ref-type="fig" rid="F5">Figure 5d</xref> shows RAP1 R133E was also defective in preventing the recruitment of LIG4, suggesting multiple contacts between RAP1, KU and DNA are required for this effect.</p><p id="P12">To examine whether inhibition of LIG4 recruitment is required for RAP1 to prevent cNHEJ at telomeres, <italic>rap1-/-apollo-/-</italic> MEFs were complemented with the RAP1 mutants examined above (<xref ref-type="fig" rid="F5">Fig 5e</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S8a-c</xref>). <xref ref-type="fig" rid="F5">Figure 5e</xref> shows RAP1 that is unable to form a complex with DNA-PK and block LIG4 recruitment could not protect telomeres from cNHEJ (<xref ref-type="supplementary-material" rid="SD1">Fig. S8c</xref>). <xref ref-type="fig" rid="F5">Figure 5f</xref> demonstrates this is also the case in human RPE-1 cells (<xref ref-type="fig" rid="F5">Fig. 5f</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S8d-g</xref>).</p><p id="P13">RAP1 is the most highly conserved component of eukaryotic chromosome ends, yet its role at mammalian telomeres has remained elusive. Our results reveal it is the defining component of an inhibitory pathway coordinated by TRF2 in which RAP1 directly and specifically supresses the end joining function of DNA-PK by preventing the recruitment of Ligase 4 (<xref ref-type="fig" rid="F5">Fig. 5g</xref>). These findings provide a molecular basis for previous studies implicating human RAP1 in chromosome end protection<sup><xref ref-type="bibr" rid="R15">15</xref>-<xref ref-type="bibr" rid="R18">18</xref></sup>, offer a mechanism for how cNHEJ can be blocked at telomeres with diverse end structures or lacking t-loops<sup><xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R39">39</xref></sup>, and resolve the long-standing paradox that DNA-PK can bind to telomeres and regulate their resection without activating cNHEJ<sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4">4</xref></sup>. By demonstrating that the assembly of DNA-PK can be functionally uncoupled from its end joining activity through LIG4 recruitment, our study also expands the mechanisms available to regulate pathway choice during double strand break repair.</p><p id="P14">Apollo and RAP1 are recruited to telomeres via TRF2, which therefore acts as a master regulator of two equally effective pathways to block cNHEJ. Why is RAP1 employed when Apollo is apparently sufficient? Processing of telomeres by Apollo depends on DNA-PK<sup><xref ref-type="bibr" rid="R23">23</xref></sup> and a TRF2 binding motif specific to vertebrate homologues<sup><xref ref-type="bibr" rid="R40">40</xref></sup>. As the RAP1:KU interaction is broadly conserved across metazoa (<xref ref-type="supplementary-material" rid="SD1">Fig. S9</xref>), we propose the pathway described here predates Apollo’s telomeric function and enabled DNA-PK at leading strand telomeres to be coopted into a resection role by preventing it from activating cNHEJ. In vertebrate cells, RAP1 will ensure DNA-PK on blunt leading strand ends cannot engage cNHEJ either before resection occurs or in instances where resection fails. There may also be scenarios in which RAP1 is the primary protective factor. For example, RAP1 deletion alone increases cNHEJ at telomeres in senescent cells<sup><xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R41">41</xref></sup>. Given that only a small number of telomeric repeats are required for TRF2 and RAP1 to prevent LIG4 recruitment in vitro (<xref ref-type="fig" rid="F5">Fig. 5b</xref>), the mechanism described here may be adept at protecting critically short telomeres in these cells from cNHEJ.</p><sec id="S1" sec-type="methods"><title>Methods</title><sec id="S2"><title>DNA templates</title><p id="P15">A 2.8 kb plasmid containing 360 bp of telomeric DNA was amplified in SURE2 <italic>E. coli</italic> cells grown at 30ºC and extracted using a QIAGEN Plasmid Maxi kit. The plasmid was linearised by BsmFI digestion for 1 hour at 37ºC leaving one end with telomeric TTAGGG repeats. The DNA was dephosphorylated with Quick-CIP for 30 min at 37ºC and cleaned up by phenol chloroform extraction and ethanol precipitation. The DNA was subsequently phosphorylated using PNK and [γ-32P]ATP for 1 hour at 37ºC, passed over a G-50 desalting column and phenol chloroform extracted. Labelled DNA was digested by SacI for 1 hour at 37ºC to isolate a 390-bp DNA fragment ending in 60 TTAGGG-repeats from the rest of the plasmid. Digested DNA was run on a 10% TBE-PAGE gel (Invitrogen) after which the telomeric fragment was excised and gel extracted by shaking in 10 mM Tris pH 8.0, 300 mM NaCl, 1 mM EDTA overnight at 21ºC. The final DNA fragment (PE1, see <xref ref-type="table" rid="T1">table 1</xref> for sequence) was isopropanol precipitated and resuspended in 1x TE buffer. A non-telomeric DNA fragment (PE2, see <xref ref-type="table" rid="T1">table 1</xref> for sequence) containing 360 bp of random DNA sequence in place of TTAGGG repeats was also prepared through the same procedure using a non-telomeric plasmid. Telomeric DNA substrates for crosslinking experiments were prepared by mixing oligonucleotides PE3 and PE4 at a 1:1 molar ratio, heating to 95ºC and slowly cooling to room temperature over 2 hours.</p></sec><sec id="S3"><title>Protein expression</title><p id="P16">Open reading frames for human KU70/80, RAP1 or TRF2 were codon optimised for <italic>S. frigiperda</italic> and cloned into pACEBAC1 vector. The mutants indicated were generated using PCR-based mutagenesis (see <xref ref-type="table" rid="T2">table 2</xref> for mutant details). The shelterin genes (TERF1, TERF2, TERF2IP/RAP1, TINF2, ACD/TPP1, POT1), codon-optimised for <italic>E. coli</italic>, were synthesised by GenScript and cloned into pACEBAC1, using a nicking cloning system<sup><xref ref-type="bibr" rid="R42">42</xref></sup>. Vectors were transposed into DH10 MultiBac Competent <italic>E. Coli</italic> cells and grown in LB medium overnight at 37ºC shaking at 200 rpm. Bacmid DNA was extracted and used to transfect Sf9 insect cells which were subsequently grown at 27ºC, shaking at 130 rpm over several cell passages. At passage three (P3), 200 ml of High Five insect cells at a 1.5 × 10<sup>6</sup> density were infected with baculoviruses for protein expression, incubating at 27°C with 130 rpm. After 3 days, the cell count was checked, and cells were harvested by centrifugation at 760 x g for 20 minutes at 4°C. Cell pellets were then resuspended in PBS, transferred into 50-ml Falcon tubes and pelleted again by centrifugation at 470 x g for 25 minutes. Supernatants were discarded, the pellets flash frozen in liquid nitrogen and placed at-80°C until required.</p></sec><sec id="S4"><title>Nuclear extract preparation</title><p id="P17">HeLa cell pellets were resuspended in buffer A (10 mM HEPES pH 8.0, 10 mM KCl,1.5 mM MgCl<sub>2</sub>, 0.5 mM DTT, 0.5 mM AEBSF) and incubated for 10 min at 4ºC. Following centrifugation at 1,033 x g for 10 min at 4ºC the pellet was resuspended in two pellet volumes of buffer A and lysed by 20 strokes in a Dounce homogeniser (pestle type B). Lysed cells were centrifuged at 25,000 x g for 20 min at 4ºC and the pellet was resuspended in 1.3x pellet volumes of buffer C (20 mM HEPES pH 8.0, 420 mM NaCl, 1.5 mM MgCl<sub>2</sub>, 0.2 mM EDTA, 25 % glycerol, 0.5 mM DTT, 0.5 mM AEBSF). Cells were resuspended by 20 strokes in a Dounce homogeniser (pestle type B), incubated for 30 min at 4ºC and centrifuged at 25,000 x g for 30 min at 4ºC. The supernatant was collected, and flash frozen in liquid nitrogen.</p></sec><sec id="S5"><title>Protein purification</title><sec id="S6"><title>DNA-PKcs purification</title><p id="P18">HeLa cell nuclear extract was diluted into DPKQ buffer (20 mM HEPES ph 7.6, 100 mM NaCl, 2 mM MgCl2, 0.5 mM EDTA, 10% glycerol, 0.5 mM DTT, 0.5 mM AEBSF) and ultracentrifuged at 50,000 x g for 1 hour at 4ºC. The supernatant was collected and filtered through a 0.45 µm syringe filter before injection onto a Q-sepharose column equilibrated in DPKQ buffer. The column was washed in DPKQ buffer and proteins were eluted using a 100 mM - 1 M NaCl gradient. Fractions were spotted onto a nitrocellulose membrane and western blotted, probing for DNA-PKcs. Fractions with DNA-PKcs were pooled, diluted into DPKQ buffer and loaded onto a heparin column equilibrated in the same buffer. The column was washed DPKQ buffer and proteins were eluted using a 100 mM - 1 M NaCl gradient. DNA-PKcs fractions were pooled, dialysed into DPKC buffer (50 mM Tris pH 7.3, 0.5 mM EDTA, 5% glycerol, 2.5 mM DTT, 0.5 mM AEBSF) with 50 mM KCl, and loaded onto a dsDNA-conjugated CNBr-activated Sepharose column equilibrated in the same buffer. The column was washed in DPKC buffer with 50 mM KCl and bound proteins were eluted in DPKC buffer with 411 mM KCl. DNA-PKcs fractions were pooled, diluted into DPKC buffer with 100 mM KCl and 0.02% Tween-20 and loaded onto a MonoQ column equilibrated in the same buffer. The column was washed in DPKC buffer with 100 mM KCl and 0.02% Tween-20 and proteins were eluted using a 100 mM - 1 M KCl gradient. DNA-PKcs fractions were pooled, diluted into DPKC buffer with 100 mM KCl and 0.02% Tween-20 and loaded onto a MonoS column equilibrated in the same buffer. The column was washed in DPKC buffer with 100 mM KCl and 0.02% Tween-20 and proteins were eluted using a 100 mM - 1 M KCl gradient. Final DNA-PKcs fractions were pooled, concentrated using a 100 kDa Amicon Ultra centrifugal filter, flash frozen in liquid nitrogen and stored at -80 ºC.</p></sec><sec id="S7"><title>KU70/80 purification</title><p id="P19">Cell pellets were resuspended in 50 mM Tris pH 8.0, 2 mM β-ME with protease inhibitor tablets and incubated stirring for 20 min at 4 ºC. Cells were lysed by the addition of 16.7% glycerol and 300 mM NaCl, stirring for 30 min at 4ºC. Lysed cells were ultracentrifuged at 125,000 x g for 30 min at 4ºC and the supernatant was incubated with anti-FLAG resin for 2 hours at 4 ºC. Beads were successively washed in Ku buffer (50 mM Tris pH 8.0, 5% glycerol, 2 mM β-ME) with 300 mM NaCl followed by Ku buffer with 150 mM NaCl. Proteins were eluted using the latter buffer supplemented with 3x FLAG peptide. Proteins were subsequently separated on a Superdex 200 gel filtration column, equilibrated and run using Ku buffer with 150 mM NaCl. Final Ku70/80 fractions were pooled, concentrated using a 30 kDa Amicon Ultra centrifugal filter, flash frozen in liquid nitrogen and stored at -80 ºC.</p></sec><sec id="S8"><title>TRF2, RAP1 and shelterin purification</title><p id="P20">For TRF2 and RAP1, cell pellets were resuspended in 50 mM HEPES pH 7.6, 1 mM DTT with EDTA-free protease inhibitor tablets (one per 50 ml - Roche) and incubated with stirring for 20 min at 4 ºC. Protein was extracted by the addition of 16.7% glycerol and 300 mM NaCl, stirring for 30 min at 4ºC. Extract was cleared by ultracentrifugation at 125,000 x g for 30 min at 4 ºC. The supernatant was applied to Strep-Tactin XT 4Flow resin equilibrated in shelterin buffer (50 mM HEPES pH 7.6, 500 mM NaCl, 10% glycerol, 1 mM DTT). Beads were washed in shelterin buffer and proteins were eluted with the same buffer supplemented with 10 mM biotin. Proteins were subsequently separated on a Superdex 200 10/300 column equilibrated and run in shelterin buffer. Final TRF2 or RAP1 fractions were pooled, concentrated using a 30 kDa Amicon Ultra centrifugal filter, flash frozen in liquid nitrogen and stored at -80 ºC. To cleave the TEB1:RAP1 fusion protein, 0.24 µM PreScission protease was incubated with 1.2 µM TEB1:RAP1 for 2 hours at 4 ºC prior to experiments. For the shelterin complex, cell pellets were resuspended in lysis buffer (50 mM Hepes pH 8.0, 300 mM NaCl, 10 % glycerol, 1 mM MgCl<sub>2</sub>, 10 mM beta-mercaptoethanol, 0.1 µl/ml Base muncher nuclease, 8 µg/ml Avidin, 1 mM AEBSF and EDTA-free protease inhibitor tablets (one per 50 ml - Roche)) and cell were lysed by sonication. Lysate was cleared by centrifugation at 48,380 x g for 1 h, 4 ºC. Cleared lysate was passed through a 0.45 µm filter and applied to a StrepTrap column equilibrated with StrepTrap wash buffer (50 mM Hepes 8.0, 300 mM NaCl, 10 glycerol and 1 mM TCEP), which was washed with 20 CV StrepTrap wash buffer prior to elution with 5 CV StrepTrap wash buffer supplemented with 10 mM d-Desthiobiotin. 0.5 ml of eluate containing the highest concentration of shelterin was applied to a Superose 6 10/300 column preequilibrated in 50 mM Hepes pH 8.0, 300 mM NaCl, 10 % glycerol and 1 mM TCEP, and run in the same buffer. The desired fractions were aliquoted and flash frozen for storage. Further characterisation of the full shelterin complex will be reported elsewhere.</p></sec><sec id="S9"><title>XRCC4/LIG4 purification</title><p id="P21">Cell pellets were resuspended in 50 mM HEPES pH 7.6, 1 mM DTT, 1mM EDTA with EDTA-free protease inhibitor tablets (Roche – 1 per 50 ml buffer) and incubated with stirring for 20 min at 4ºC. Proteins were extracted by the addition of glycerol to 16.7% and NaCl to 300 mM with stirring for 30 min at 4ºC. Extract was centrifuged at 41,656 x g for 30 min at 4ºC and the supernatant was applied to Strep-Tactin XT 4Flow resin equilibrated in X4 buffer (50 mM HEPES pH 7.6, 300 mM NaCl, 10 % glycerol, 1 mM DTT, 1mM EDTA). Beads were washed in X4 buffer and proteins were eluted with the same buffer supplemented with 30 mM biotin. Protein fractions were pooled, the NaCl concentration diluted to 100mM then applied to a 1 ml heparin column and subjected to a linear gradient from 0.1 M to 1 M NaCl over 20 column volumes. Proteins were subsequently separated on a Superdex 200 gel filtration column equilibrated and run in 100mM NaCl buffer (50 mM HEPES pH 7.6, 100 mM NaCl, 10% glycerol, 1 mM DTT, 1mM EDTA). Final XRCC4/LIG4 fractions were pooled, concentrated using a 30 kDa Amicon Ultra centrifugal filter, flash frozen in liquid nitrogen and stored at -80 ºC.</p></sec></sec><sec id="S10"><title>Nano differential scanning fluorimetry</title><p id="P22">Purified proteins as indicated were analysed by nano differential scanning fluorometry to assess thermal protein stability using a Tycho NT.6 (Nanotemper) with 10 µl capillaries, monitoring fluorescence at 330 and 350 nm over a 35-95ºC temperature ramp (30 °C/min).</p></sec><sec id="S11"><title>DNase I footprinting</title><p id="P23">2 nM [γ-<sup>32</sup>P]-PNK-labelled PE1 (telomeric) or PE2 (non-telomeric) template was mixed with 30 nM DNA-PKcs and 50 nM KU70/80 in 25 mM HEPES pH 7.6, 80 mM KCl, 1.5 mM CaCl<sub>2</sub>, 1.5 mM MgCl<sub>2</sub>, 5% glycerol, 50 µg/ml BSA, 2 mM DTT and incubated on ice for 5 min. 5 nM shelterin or TRF2:RAP1 (dimer concentration of TRF2) was added to DNA-bound DNA-PK and incubated at 37 ºC for 10 min. Nuclease cleavage was initiated by addition of DNaseI to 0.5 U/ml and the reactions were incubated for a further 2 min at 37ºC before quenching with 25 mM EDTA, 0.2% SDS, 0.2 mg/ml Proteinase K. Following incubation at 37 ºC for 10 min, samples were extracted with phenol chloroform, ethanol precipitated and resuspended in 2 µl 99% formamide, 5 mM EDTA, bromophenol blue. Samples were boiled for 2 min and run on an 8% urea-PAGE sequencing gel in 1x TBE.</p></sec><sec id="S12"><title>Electrophoretic Mobility Shift Assay</title><p id="P24">1 nM [γ-<sup>32</sup>P]-labelled telomeric DNA was mixed with 2, 10 or 40 nM TRF2 or RAP1 in 25 mM HEPES ph 7.6, 80 mM KCl, 1.5 mM CaCl<sub>2</sub>, 1.5 mM MgCl<sub>2</sub>, 5% glycerol, 50 µg/ml BSA, 2 mM DTT. 10 µl reactions were incubated at 37ºC for 15 min. Samples were supplemented with 1% sucrose, Orange G and run on a 1.5 % agarose gel in 0.5x TBE.</p></sec><sec id="S13"><title>Crosslinking</title><p id="P25">200 nM KU70/80 was mixed with 200 nM RAP1 in 20 mM HEPES pH 7.6, 200 nM NaCl, 2 mM MgCl<sub>2</sub>, 0.5 mM EDTA, 10% glycerol, 0.5 mM DTT, 0.5 mM AEBSF and incubated for 5 min at 4ºC. Samples were supplemented by 100 nM annealed DNA substrates and incubated for 10 min at 4 ºC. Proteins were crosslinked by addition of 2 mM DSSO and incubated for 60 min at room temperature. Reactions were stopped with 20 mM Tris pH 7.6. Samples were run on a Criterion XT 3-8% Tris-Acetate PAGE gel in 1x XT Tricine and analysed by silver staining (SilverQuest, Invitrogen) or immunoblotting, probing for KU70 or RAP1.</p></sec><sec id="S14"><title>DNA-PK Pulldown</title><p id="P26">10 nM KU70/80 and 15 nM DNA-PKcs were incubated with 5 nM annealed DNA oligos (see <xref ref-type="sec" rid="S2">‘DNA templates’</xref>) for 3 min at 30°C in 25 mM HEPES pH 7.6, 80 mM KCl, 10 % glycerol, 0.02 % NP-40 and 1 mM DTT in a final volume of 25 µl. 5 nM TRF2:RAP1 complex was added, and after a further 3 min, 30 nM XRCC4:LIG4 complex was added. After a further 3 min, the complete reaction was added to 1 µl equivalent of anti-FLAG M2 magnetic beads (Sigma), and the mixture incubated at 4 ºC with shaking for 30 min. Beads were pelleted on a magnetic rack, washed 3x with 50 µl 25 mM HEPES pH 7.6, 80 mM KCl, 10 % glycerol, 0.02 % NP-40 and 1 mM DTT with a brief vortex included for each wash. Beads were resuspended in wash buffer supplemented with 0.25 mg/ml 3x FLAG peptide and incubated for 20 min at 18 ºC with shaking. Eluted proteins were supplemented with SDS loading buffer, run on a 4-12 % TGX precast gel (Biorad), proteins transferred onto nitrocellulose membrane at 80 V for 90 min and detected by immunoblotting with the antibodies indicated.</p></sec><sec id="S15"><title>Cryo-EM sample preparation</title><p id="P27">Annealed PE03 and PE04 (see <xref ref-type="sec" rid="S2">‘DNA templates’</xref>) were mixed 1:1 with streptavidin in TE buffer and incubated for 30 min at room temperature. Streptavidin-bound DNA was diluted to 250 nM in 40 mM HEPES pH 7.6, 100 mM NaCl, 3 mM MgCl2, 1 mM DTT, 2.5% glycerol and incubated with 250 nM KU70/80 and 250 nM DNA-PKcs for 10 min at 4 ºC. 250 nM TRF2:RAP1 (dimer concentration of TRF2) was added and incubated for another 5 min at 4ºC. Samples were supplemented with 0.05% CHAPS prior to cryo-EM grid preparation.</p></sec><sec id="S16"><title>Cryo-EM data acquisition and image processing</title><p id="P28">300-mesh copper R1.2/1.3 grids (Quantifoil) were coated with a thin layer or carbon and glow-discharged at 15 mA for 30 s (PELCO easiGlow). 3 µl sample was applied to glow-discharged grids and incubated for 5 s followed by blotting for 3 sec using a Vitrobot Mark IV (FEI ThermoFisher) operated at 4 ºC and 100% humidity. Grids were subsequently plunge-frozen in liquid ethane. Cryo-EM data were acquired at 200 kV on a Glacios Cryo-TEM equipped with a Falcon 4i Direct Electron Detector. 30,604 movies with 30 frames were collected at x150,000 magnification (0.94 Å pixel size) with a total electron dose of 50 e<sup>-</sup>/Å<sup><xref ref-type="bibr" rid="R2">2</xref></sup> and a defocus range of −1.0 to −2.5 μm. Subsequent image processing was performed in cryoSPARC (v4.3.1)<sup><xref ref-type="bibr" rid="R43">43</xref></sup>. Movies were motion corrected using patch alignment with all frames followed by patch CTF estimation. Particles were picked through automated template-based picking (template EMD-6803) and extracted with x4 binning using a box size of 96 pixels. Following 2D classification 1,464,362 DNA-PK particles were selected to reconstruct an ab-initio 3D model, subsequently used as a starting model for heterogeneous refinement using 5 classes. The most prominent DNA-PK class was selected and subjected to homogeneous refinement followed by local refinement using a focus mask encompassing the KU70/80:DNA core. 3D classification without alignment using the same mask and 10 classes was performed to identify particles containing additional Rap1 and KU densities. Classes lacking either the RAP1 BRCT, the RAP1 myb or the KU70 SAP domain were excluded. 526,885 selected particles were re-extracted unbinned with a 384-pixel box size and a 3D map was reconstructed through homogeneous refinement. Following global CTF refinement a structure of the full DNA end-binding complex was resolved to 3.58 Å using homogeneous refinement. The KU:RAP1:DNA core was locally refined to 3.32 Å using a focus mask excluding DNA-PKcs. The DNA-PKcs:DNA density was similarly refined using a mask excluding the KU-RAP1-DNA core and subjected to 3D classification without alignment using the same mask. Some flexibility in DNA-PKcs conformation was observed and classes of the most prominent conformation containing 370,172 paricles were selected. A DNA-PKcs:DNA structure from these particles was resolved to 3.40 Å by homogeneous refinement followed by local refinement using a DNA-PKcs focus mask. Maps for the full end-binding complex and the locally refined densities were sharpened in cryoSPARC and combined using Phenix (v1.20.1) combine_focused_maps<sup><xref ref-type="bibr" rid="R44">44</xref></sup>. The composite map (EMD-19065) was subsequently used for model building in Coot<sup><xref ref-type="bibr" rid="R45">45</xref></sup> and figure generation in ChimeraX<sup><xref ref-type="bibr" rid="R46">46</xref></sup>.</p></sec><sec id="S17"><title>Model Building and Validation</title><p id="P29">Molecular models for human DNA-PK (PBD 7K1K), RAP1 myb (PDB 1FEX) and KU70 SAP (PDB 1JJR) were docked into the cryo-EM map using the Fit in Map command in ChimeraX<sup><xref ref-type="bibr" rid="R46">46</xref></sup>. The RAP1 BRCT domain from a KU:RAP1 Alphafold model (see below) was similarly docked into the cryo-EM map. Models were refined against the map using Namdinator<sup><xref ref-type="bibr" rid="R47">47</xref></sup> followed by manual inspection in Coot<sup><xref ref-type="bibr" rid="R45">45</xref></sup>. Unoccupied protein densities and nucleic acids were modelled de novo. The resulting model was iteratively refined using Phenix (v1.20.1) real_space_refinement<sup><xref ref-type="bibr" rid="R48">48</xref></sup> with geometry and secondary structure restraints followed by manual adjustment in Coot. The quality of the final atomic model (PDB 8RD4) was evaluated by MolProbity<sup><xref ref-type="bibr" rid="R49">49</xref></sup> (see <xref ref-type="table" rid="T3">table 3</xref>).</p></sec><sec id="S18"><title>Alphafold modelling</title><p id="P30">Full length human RAP1, KU70 and KU80 were analysed using Alphafold 3 on the online Alphafold server.</p></sec><sec id="S19"><title>Protein alignments</title><p id="P31">Pre-computed protein alignments were analysed using the Proviz online tool<sup><xref ref-type="bibr" rid="R50">50</xref></sup></p></sec><sec id="S20"><title>Antibodies used</title><p id="P32">Human DNA-PKcs was detected with antibody 18-2 (Invitrogen MA5-13238). Recombinant human KU70 was detected via an N-terminal FLAG-tag with antibody M2 (Sigma F1804). Recombinant human LIG4, TRF2 and RAP1 were detected via a dual strep tag using antibody (Abcam ab76949). Recombinant human XRCC4 was detected with antibody C-4 (Santa Cruz sc-271087). Mouse RAP1 was detected with antibody D9H4 (Rabbit mAb #5433), human RAP1 with A300-306A antibody (Bethyl Laboratories) mouse and human TRF2 with D1Y5D (Cell Signaling 13136), and Donkey anti-Rabbit IgG horseradish peroxidase (NA934V, Cytiva) or Goat anti-Rabbit IgG horseradish peroxidase (31460, Invitrogen) secondary antibodies. Mouse β-actin was detected with primary antibody C4 (Cell Signaling #3700) and Goat anti-Mouse IgG horseradish peroxidase (31430, Invitrogen) secondary antibody. Human Apollo was detected with HPA064934 (Atlas Antibodies).</p></sec><sec id="S21"><title>Cell lines and Viral gene delivery</title><p id="P33">SV40-LT <italic>Apollo</italic><sup>F/F</sup> Lig4<sup>+/+</sup>, <italic>Apollo</italic><sup>F/F</sup> Lig4<sup>-/-</sup>, and <italic>Trf2</italic><sup>F/F</sup><italic>Rosa26Cre-ER</italic><sup>T1</sup> MEFs have been previously described (Wu et al, 2010; Lottersberger et al, 2015). hTERT immortalized RPE-1 cells have been previously described<sup><xref ref-type="bibr" rid="R51">51</xref></sup> All MEFs were immortalized with pBabeSV40LargeT and cultured in Dulbecco’s Modified Eagle Medium (DMEM, Cytiva) supplemented with 15% fetal bovine serum (FBS, Gibco), non-essential amino acids (Cytiva), L-glutamine (Cytiva), penicillin/streptomycin (Cytiva), 50 µM β-mercaptoethanol (Sigma). 293T and Phoenix eco cells (ATCC, Rockville, MD) were cultured in DMEM (Cytiva) supplemented with 10% HyClone Bovine Calf Serum (Cytiva), non-essential amino acids (Cytiva), L-glutamine (Cytiva), and penicillin/streptomycin (Cytiva). RPE-1 cells were cultured in DMEM/F12 supplemented with 10% (v/v) FBS, 1% (v/v) penicillin-streptomycin, 1% Glutamax, 0.5ug/ml Amphotericin B and 0.26% sodium bicarbonate. To generate p53-/- clones by CRISPR-Cas9 mediated gene editing, RPE-1 cells were electroporated with Cas9:sgRNA ribonucleoparticles targeting the sequences 5’-AAATTTGCGTGTGGAG TATT-3’ and 5’-TCCACTCGGATAAGATGCTG-3’<sup><xref ref-type="bibr" rid="R52">52</xref></sup> using the Neon Transfection system as described (Cirillo et al, 2024). After four days, cells were single sorted into 96-well plates containing medium supplemented with 10 µM nutlin-3a. After 14 days, surviving clones were expanded, and p53 status analysed by immunoblotting and sequencing of the TP53 locus as described<sup><xref ref-type="bibr" rid="R52">52</xref></sup>. CRISPR-Cas9 mediated gene editing of human RAP1 in p53-/- RPE-1 cells was carried out using phosphorothioated single-stranded DNA repair templates (ssODN) and selection for positive integrands by ouabain as described<sup><xref ref-type="bibr" rid="R53">53</xref>,<xref ref-type="bibr" rid="R54">54</xref></sup>. Briefly, RAP1 guide RNA 5’-GGCCCAGCCCGGCCAAGCGT-3’ was cloned into the BspI site of Addgene vector 86613. Repair templates for ATPA1 and RAP1 were synthesised by Integrated DNA Technologies (IDT) with the following sequences: ATP1A1: C*A*ATGTTACTGTGGATTGGAGCGATTCTTTGTTTCTTGGCTTATAGCATCAGA GCTGCTACAGAAGAGGAACCTCAAAACGATGACGTGAGTTCTGTAATTCAGCAT ATCGATTTGTAGTACACATCAGATATC*T*T. RAP1: C*A*TTCCTCGACTCTGTT CGTGAGGGACGACGGCAGCTCCATGTCCTTCTACGTGCGGCCCAGCCCGGCC GACGAGCGCCTCTCGACGCTCATCCTGCACGGCGGCGGCACGGTGTGCGAGG TGCAGGAGCCCGGGGCCGTGCTGCTGGCCCAGCCCGGGGAGGCGCTGGCCG AGGCCTCGGGTGATTTCATCTCCACG*C*A. where * denotes a phosphorthiolated base. To generate RAP1 KR/DE clones, 300,000 p53-/- RPE-1 cells were electroporated with the Neon Transfection System using a 10 µl tip and two pulses at 1350 V and 20 ms with 500 ng RAP1 gRNA/Addgene: 86613 plasmid, 2 pmol of ATP1A1 ssODN and 6 pmol RAP1 ssODN. To generate RAP1-/- clones, the procedure was repeated but omitting RAP1 ssODN. After 3-4 days, cells were expanded into 15 cm dished and treated with 0.25 µM ouabain, followed by isolation of single clones 7-12 days after drug selection. Genomic DNA was prepared using EZNA Tissue DNA kit according to the manufacturer’s instructions. <italic>RAP1</italic> was amplified by PCR using oligo sequences AGTGCTGCGCTTCGCGGC and CGCCTTCCGCTTGAGCTTCTG. Editing was analysed by restriction digestion with SalI and Sanger sequencing, and positive clones single cell sorted and expanded prior to freezing. For retro or lentiviral transduction, a total of 20 µg of plasmid DNA was transfected into Phoenix eco or 293T cells, respectively, using CaPO<sub>4</sub> precipitation. The viral supernatant was filtered through a 0.45-μm filter, supplemented with 4 μg/ml polybrene, and used for the transduction of target cells. Lentiviral particles containing the sgRNA against mouse Rap1 (target: 5’-GCAGTCTAGGATGTACTGCG-3’) in lentiCRISPR v2 (Addgene plasmid # 52961, a gift from Feng Zhang) were introduced into target MEFs cells with three infections/day (6-12 h intervals) over 2 days, followed by 2 days in 2-4 µM Puromycin or 340 µM Hygromycin. The same approach was also used to target human Apollo in p53-/- RPE-1 cells with lentiviral particles containing lentiCRISPR v2 with the guide sequence 5’-CTGGTTCCAACGCAGCATGT-3’<sup><xref ref-type="bibr" rid="R23">23</xref></sup>, or non-targeting control sequence 5’-CGCCAAACGTGCCCTGACGG-3’. Cre was induced with three infections/day (6-12 h intervals) over two days with pMMP Hit &amp; Run Cre retrovirus produced in Phoenix eco cells. Time-point 0 was set 12 hrs after the first Hit &amp; Run Cre infection. For the Rap1-complementation assay, <italic>Apollo</italic><sup><italic>F/F</italic></sup> MEFs were transduced with retroviral particle containing <italic>Rap1, Rap1</italic><sup><italic>KR/DE</italic></sup> or <italic>Rap1</italic><sup><italic>R130E</italic></sup> cloned in Plpc vector for a total of 4 infections at 6–12-h intervals, selected for 2-3 days in 2-4 µM Puromycin, transduced with the sgRNA against mouse Rap1 cloned in LcV2-Hygro (Addgene plasmid # 91977, a gift from Joshua Mendell), selected for 2 days in 340 µM Hygromycin and then transduced with pMMP Hit &amp; Run Cre as previously described. For the Trf2-complementation assays, <italic>Trf2</italic><sub>F/F</sub><italic>Rosa26Cre-ER</italic><sub>T1</sub> MEFs were transduced with retroviral particle containing the Trf2 mutants, selected for 2 days in 2-4 µM Puromycin and then treated with 1 μM 4-OHT for 24 h. Time-point 0 was set at the time of 4-OHT addition.</p></sec><sec id="S22"><title>Generation of Trf2 mutant alleles</title><p id="P34">PCR was used to delete the Rap1 binding motif (RBM) or insert the S367A mutation in the MYC-tagged Trf2, Trf2<sup>F120A</sup>, Trf2<sup>ΔiDDR</sup> and Trf2<sup>F120A ΔiDDR</sup> alleles cloned in pLPC retroviral vector (Chen et al, 2008; Myler and Toia et al, 2023) using the following primers: Trf2<sup>ΔRBM</sup>-F: 5′-AATCTGGCATCCCCATCATCAC -3′ Trf2<sup>ΔRBM</sup>-R: 5′-TCTG CTTGGAGGCTCTCTAAG -3′ Trf2<sup>S367A</sup>-F: 5′-GCGCCAGCCCACAAACACAAGAGA CC -3′ Trf2<sup>S367A</sup>-R: 5′-TGATGGGGATGCCAGATTAGCAAG-3′</p></sec><sec id="S23"><title>Fluorescence In Situ Hybridization (FISH)</title><p id="P35">FISH on mouse and human cells was performed as previously described<sup><xref ref-type="bibr" rid="R55">55</xref></sup>. Briefly, cells were treated treated with 0.2 µg/ml Colcemid (Biowest/Roche) for 2 hours before collection by trypsinization. Harvested cells were swollen in a hypotonic solution of 0.075M KCl at 37 °C for 20 minutes before fixation in methanol/acetic acid (3:1) overnight at 4 °C. Cells were dropped onto glass slides and allowed to age overnight. The slides were then dehydrated through an ethanol series of 70%, 95%, and 100% and allowed to air-dry. Telomere ends were hybridized with Cy3-OO-(TTAGGG)3 in hybridization solution (70% formamide, 1 mg/ml blocking reagent (1109617601, Roche), and 10 mM Tris-HCl pH 7.2) for 2 hours following an initial 5-10 min denaturation step at 80°C, washed twice with 70% formamide; 0.1% BSA; 10 mM Tris-HCl, pH 7.2 for 15 minutes each, and thrice in 0.08% Tween-20; 0.15 M NaCl; 0.1 M Tris-HCl, pH 7.2 or PBS for 5 minutes each. Chromosomal DNA was counterstained with the addition of DAPI (D1306, Invitrogen) to the second wash. Slides were left to air-dry and mounted in antifade reagent (Prolong Gold Antifade P36934, Fisher). coFISH analysis was performed as previously described<sup><xref ref-type="bibr" rid="R23">23</xref></sup> with the following modifications: RPE-1 cells were treated with BrdU:BrdC for 14 h, slides were treated with UV for 10 minutes using a Blak ray model UV-21 365 nm handheld lamp at a distance of 8 cm and telomeres were detected with Cy3-OO-(TTAGGG)3 and FITC-OO-(CCCTAA)3.</p></sec><sec id="S24"><title>Immunoblotting</title><p id="P36">Cells were lysed in 2 x Laemmli buffer at 5×103 or 1×104 cells/μl and the lysate was denatured for 10 min at 95 °C before shearing with an insulin needle or sonication. Lysate equivalent to 1-2×105 cells was resolved using SDS/PAGE and transferred to a nitrocellulose membrane. Western blot was performed with 5% milk in PBS containing 0.1% (v/v) Tween-20 (PBS-T) with reagents described in the ‘antibodies used’ section. Signal was detected according to the manufacturer’s instructions using chemiluminescence western blotting detection reagents (Cytiva) using ChemiDoc (Bio-Rad) imaging systems.</p></sec><sec id="S25"><title>Chemical crosslinking mass spectrometry analysis</title><p id="P37">Complex assembly and crosslinking with DSSO was performed as described in the ‘Crosslinking’ section. After the crosslinking reaction, triethylammonium bicarbonate buffer (TEAB) was added to the sample at a final concentration of 100 mM. Proteins were reduced and alkylated with 5 mM tris-2-carboxyethyl phosphine (TCEP) and 10 mM iodoacetamide (IAA) simultaneously and digested overnight with trypsin at final concentration 50 ng/μL (Pierce). Sample was dried and peptides were fractionated with high-pH Reversed-Phase (RP) chromatography using the XBridge C18 column (1.0 × 100 mm, 3.5 μm, Waters) on an UltiMate 3000 HPLC system. Mobile phase A was 0.1% v/v ammonium hydroxide and mobile phase B was acetonitrile, 0.1% v/v ammonium hydroxide. The peptides were fractionated at 70 μL/min with the following gradient: 5 minutes at 5% B, up to 15% B in 3 min, for 32 min gradient to 40% B, gradient to 90% B in 5 min, isocratic for 5 minutes and re-equilibration to 5% B. Fractions were collected every 100 sec, SpeedVac dried and pooled into 12 samples for MS analysis. LC-MS analysis was performed on an UltiMate 3000 UHPLC system coupled with the Orbitrap Ascend Mass Spectrometer (Thermo). Each peptide fraction was reconstituted in 30 μL 0.1% formic acid and 15 μL were loaded to the Acclaim PepMap 100, 100 μm × 2 cm C18, 5 μm trapping column at 10 μL/min flow rate of 0.1% formic acid loading buffer. Peptides were then subjected to a gradient elution on the Acclaim PepMap (75 μm × 50 cm, 2 μm, 100 Å) C18 capillary column connected to the EASY-Spray source at 45 °C with an EASY-Spray emitter (Thermo, ES991). Mobile phase A was 0.1% formic acid and mobile phase B was 80% acetonitrile, 0.1% formic acid. The gradient separation method at flow rate 300 nL/min was as follows: for 80 min gradient from 5%-35% B, for 5 min up to 95% B, for 5 min isocratic at 95% B, re-equilibration to 5% B in 5 min, for 5 min isocratic at 5% B. Precursors between 380-1,400 m/z and charge states 3-8 were selected at 120,000 resolution in the top speed mode in 3 sec and were isolated for stepped HCD fragmentation (collision energies % = 21, 27, 34) with quadrupole isolation width 1.6 Th, Orbitrap detection with 30,000 resolution and 70 ms Maximum Injection Time. Targeted MS precursors were dynamically excluded from further isolation and activation for 45 seconds with 10 ppm mass tolerance. Identification of crosslinked peptides was performed in Proteome Discoverer 2.4 (Thermo) with the Xlinkx search engine in the MS2 mode for DSSO / +158.004 Da (K). Precursor and fragment mass tolerances were 10 ppm and 0.02 Da respectively with maximum 2 trypsin missed cleavages allowed. Carbamidomethyl at C was selected as static modification. Spectra were searched against a UniProt FASTA file containing Homo sapiens reviewed entries. Crosslinked peptides were filtered at FDR&lt;0.01 using the Percolator node and target-decoy database search.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary data</label><media xlink:href="EMS202434-supplement-Supplementary_data.pdf" mimetype="application" mime-subtype="pdf" id="d152aAcObB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Supplementary Video 1 Legend</label><media xlink:href="EMS202434-supplement-Supplementary_Video_1_Legend.pdf" mimetype="application" mime-subtype="pdf" id="d152aAcOcB" position="anchor"/></supplementary-material></sec></body><back><ack id="S26"><title>Acknowledgements</title><p>The authors are grateful to Peter Martin, Ronan Broderick, Alex Radzisheuskaya and Hannah Mischo for reagents and advice and to Gideon Coster and Titia de Lange for comments on the manuscript. M.E.D is funded by a Cancer Research UK Career Development Award (C68409/A28129). F.L. is supported by grants from Cancerfonden (21 1732 Pj), Vetenskapsrådet (2021-02788) and Knut and Alice Wallenberg Foundation. J.M. is funded by a Cancer Research UK Senior Cancer Research Fellowship (RCCSCF-Nov22/100001).</p></ack><fn-group><fn fn-type="con" id="FN1"><p id="P38"><bold>Author contributions</bold></p><p id="P39">M.E.D conceived the study, with genetic experiments devised in collaboration with F.L. Mouse embryonic fibroblast experiments were performed by C.S. with help from A.d.S. RPE-1 cell experiments were performed by M.E.D and P.E. with advice from J.M. Experiments in <xref ref-type="fig" rid="F2">figures 2</xref>, <xref ref-type="fig" rid="F3">3</xref> and <xref ref-type="fig" rid="F5">5</xref> were performed by P.E with help from C.E.L.F. For <xref ref-type="fig" rid="F2">figure 2b</xref>, S.G. designed the expression construct for shelterin, which was purified by O.I. Samples for <xref ref-type="fig" rid="F4">figure 4</xref> were prepared by P.E and C.E.L.F; O.I prepared and screened grids and P.E and C.E.L.F performed data processing. T.I.R performed cross-linking mass spectrometry for <xref ref-type="supplementary-material" rid="SD1">figure S5</xref>, on a sample prepared by P.E. Supervision was provided by J.S.C, S.G, F.L and M.E.D. The manuscript was written by M.E.D, with input from all authors.</p></fn><fn fn-type="conflict" id="FN2"><p id="P40"><bold>Competing interests</bold></p><p id="P41">None declared.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>HHY</given-names></name><name><surname>Pannunzio</surname><given-names>NR</given-names></name><name><surname>Adachi</surname><given-names>N</given-names></name><name><surname>Lieber</surname><given-names>MR</given-names></name></person-group><article-title>Non-homologous DNA end joining and alternative pathways to double-strand break repair</article-title><source>Nat Rev Mol Cell Biol</source><year>2017</year><volume>18</volume><fpage>495</fpage><lpage>506</lpage><pub-id pub-id-type="pmcid">PMC7062608</pub-id><pub-id pub-id-type="pmid">28512351</pub-id><pub-id pub-id-type="doi">10.1038/nrm.2017.48</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><article-title>Shelterin-Mediated Telomere Protection</article-title><source>Annu Rev Genet</source><year>2018</year><volume>52</volume><fpage>223</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">30208292</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>HL</given-names></name><name><surname>Gilley</surname><given-names>D</given-names></name><name><surname>Blackburn</surname><given-names>EH</given-names></name><name><surname>Chen</surname><given-names>DJ</given-names></name></person-group><article-title>Ku is associated with the telomere in mammals</article-title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><fpage>12454</fpage><lpage>12458</lpage><pub-id pub-id-type="pmcid">PMC22947</pub-id><pub-id pub-id-type="pmid">10535943</pub-id><pub-id pub-id-type="doi">10.1073/pnas.96.22.12454</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>d'Adda di Fagagna</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effects of DNA nonhomologous end-joining factors on telomere length and chromosomal stability in mammalian cells</article-title><source>Curr Biol</source><year>2001</year><volume>11</volume><fpage>1192</fpage><lpage>1196</lpage><pub-id pub-id-type="pmid">11516951</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denchi</surname><given-names>EL</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><article-title>Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1</article-title><source>Nature</source><year>2007</year><volume>448</volume><fpage>1068</fpage><lpage>1071</lpage><pub-id pub-id-type="pmid">17687332</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>GB</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><article-title>DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion</article-title><source>Nat Cell Biol</source><year>2005</year><volume>7</volume><fpage>712</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">15968270</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stansel</surname><given-names>RM</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name><name><surname>Griffith</surname><given-names>JD</given-names></name></person-group><article-title>T-loop assembly in vitro involves binding of TRF2 near the 3’ telomeric overhang</article-title><source>EMBO J</source><year>2001</year><volume>20</volume><fpage>5532</fpage><lpage>5540</lpage><pub-id pub-id-type="pmcid">PMC125642</pub-id><pub-id pub-id-type="pmid">11574485</pub-id><pub-id pub-id-type="doi">10.1093/emboj/20.19.5532</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soudet</surname><given-names>J</given-names></name><name><surname>Jolivet</surname><given-names>P</given-names></name><name><surname>Teixeira</surname><given-names>MT</given-names></name></person-group><article-title>Elucidation of the DNA end-replication problem in Saccharomyces cerevisiae</article-title><source>Mol Cell</source><year>2014</year><volume>53</volume><fpage>954</fpage><lpage>964</lpage><pub-id pub-id-type="pmid">24656131</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiro Takai</surname><given-names>VA</given-names></name><name><surname>Pamela</surname><given-names>Borges</given-names></name><name><surname>Joseph</surname><given-names>TP</given-names></name><name><surname>de Lange</surname><given-names>Titia</given-names></name></person-group><article-title>CST– Polymeraseα-primase solves a second telomere end-replication problem</article-title><source>Biorxiv</source><year>2023</year><pub-id pub-id-type="pmcid">PMC11160940</pub-id><pub-id pub-id-type="pmid">38418884</pub-id><pub-id pub-id-type="doi">10.1038/s41586-024-07137-1</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Takai</surname><given-names>H</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><article-title>Telomeric 3’ overhangs derive from resection by Exo1 and Apollo and fill-in by POT1b-associated CST</article-title><source>Cell</source><year>2012</year><volume>150</volume><fpage>39</fpage><lpage>52</lpage><pub-id pub-id-type="pmcid">PMC3392515</pub-id><pub-id pub-id-type="pmid">22748632</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2012.05.026</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>van Overbeek</surname><given-names>M</given-names></name><name><surname>Rooney</surname><given-names>S</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><article-title>Apollo contributes to G overhang maintenance and protects leading-end telomeres</article-title><source>Mol Cell</source><year>2010</year><volume>39</volume><fpage>606</fpage><lpage>617</lpage><pub-id pub-id-type="pmcid">PMC2929323</pub-id><pub-id pub-id-type="pmid">20619712</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2010.06.031</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>YC</given-names></name><etal/></person-group><article-title>SNMIB/Apollo protects leading-strand telomeres against NHEJ-mediated repair</article-title><source>EMBO J</source><year>2010</year><volume>29</volume><fpage>2230</fpage><lpage>2241</lpage><pub-id pub-id-type="pmcid">PMC2905253</pub-id><pub-id pub-id-type="pmid">20551906</pub-id><pub-id pub-id-type="doi">10.1038/emboj.2010.58</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myler</surname><given-names>LR</given-names></name><etal/></person-group><article-title>DNA-PK and the TRF2 iDDR inhibit MRN-initiated resection at leading-end telomeres</article-title><source>Nat Struct Mol Biol</source><year>2023</year><volume>30</volume><fpage>1346</fpage><lpage>1356</lpage><pub-id pub-id-type="pmcid">PMC10497418</pub-id><pub-id pub-id-type="pmid">37653239</pub-id><pub-id pub-id-type="doi">10.1038/s41594-023-01072-x</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardo</surname><given-names>B</given-names></name><name><surname>Marcand</surname><given-names>S</given-names></name></person-group><article-title>Rap1 prevents telomere fusions by nonhomologous end joining</article-title><source>EMBO J</source><year>2005</year><volume>24</volume><fpage>3117</fpage><lpage>3127</lpage><pub-id pub-id-type="pmcid">PMC1201357</pub-id><pub-id pub-id-type="pmid">16096640</pub-id><pub-id pub-id-type="doi">10.1038/sj.emboj.7600778</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarthy</surname><given-names>J</given-names></name><name><surname>Bae</surname><given-names>NS</given-names></name><name><surname>Scrafford</surname><given-names>J</given-names></name><name><surname>Baumann</surname><given-names>P</given-names></name></person-group><article-title>Human RAP1 inhibits non-homologous end joining at telomeres</article-title><source>EMBO J</source><year>2009</year><volume>28</volume><fpage>3390</fpage><lpage>3399</lpage><pub-id pub-id-type="pmcid">PMC2776107</pub-id><pub-id pub-id-type="pmid">19763083</pub-id><pub-id pub-id-type="doi">10.1038/emboj.2009.275</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lototska</surname><given-names>L</given-names></name><etal/></person-group><article-title>Human RAP1 specifically protects telomeres of senescent cells from DNA damage</article-title><source>EMBO Rep</source><year>2020</year><volume>21</volume><elocation-id>e49076</elocation-id><pub-id pub-id-type="pmcid">PMC7132343</pub-id><pub-id pub-id-type="pmid">32096305</pub-id><pub-id pub-id-type="doi">10.15252/embr.201949076</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>NS</given-names></name><name><surname>Baumann</surname><given-names>P</given-names></name></person-group><article-title>A RAP1/TRF2 complex inhibits nonhomologous end-joining at human telomeric DNA ends</article-title><source>Mol Cell</source><year>2007</year><volume>26</volume><fpage>323</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">17499040</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bombarde</surname><given-names>O</given-names></name><etal/></person-group><article-title>TRF2/RAP1 and DNA-PK mediate a double protection against joining at telomeric ends</article-title><source>EMBO J</source><year>2010</year><volume>29</volume><fpage>1573</fpage><lpage>1584</lpage><pub-id pub-id-type="pmcid">PMC2876953</pub-id><pub-id pub-id-type="pmid">20407424</pub-id><pub-id pub-id-type="doi">10.1038/emboj.2010.49</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabir</surname><given-names>S</given-names></name><name><surname>Hockemeyer</surname><given-names>D</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><article-title>TALEN gene knockouts reveal no requirement for the conserved human shelterin protein Rap1 in telomere protection and length regulation</article-title><source>Cell Rep</source><year>2014</year><volume>9</volume><fpage>1273</fpage><lpage>1280</lpage><pub-id pub-id-type="pmcid">PMC4254571</pub-id><pub-id pub-id-type="pmid">25453752</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2014.10.014</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sfeir</surname><given-names>A</given-names></name><name><surname>Kabir</surname><given-names>S</given-names></name><name><surname>van Overbeek</surname><given-names>M</given-names></name><name><surname>Celli</surname><given-names>GB</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><article-title>Loss of Rap1 induces telomere recombination in the absence of NHEJ or a DNA damage signal</article-title><source>Science</source><year>2010</year><volume>327</volume><fpage>1657</fpage><lpage>1661</lpage><pub-id pub-id-type="pmcid">PMC2864730</pub-id><pub-id pub-id-type="pmid">20339076</pub-id><pub-id pub-id-type="doi">10.1126/science.1185100</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>P</given-names></name><etal/></person-group><article-title>Mammalian Rap1 controls telomere function and gene expression through binding to telomeric and extratelomeric sites</article-title><source>Nat Cell Biol</source><year>2010</year><volume>12</volume><fpage>768</fpage><lpage>780</lpage><pub-id pub-id-type="pmcid">PMC3792482</pub-id><pub-id pub-id-type="pmid">20622869</pub-id><pub-id pub-id-type="doi">10.1038/ncb2081</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kermasson</surname><given-names>L</given-names></name><etal/></person-group><article-title>Inherited human Apollo deficiency causes severe bone marrow failure and developmental defects</article-title><source>Blood</source><year>2022</year><volume>139</volume><fpage>2427</fpage><lpage>2440</lpage><pub-id pub-id-type="pmcid">PMC11022855</pub-id><pub-id pub-id-type="pmid">35007328</pub-id><pub-id pub-id-type="doi">10.1182/blood.2021010791</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonmez</surname><given-names>C</given-names></name><etal/></person-group><article-title>DNA-PK controls Apollo’s access to leading-end telomeres</article-title><source>Nucleic Acids Res</source><year>2024</year><volume>52</volume><fpage>4313</fpage><lpage>4327</lpage><pub-id pub-id-type="pmcid">PMC11077071</pub-id><pub-id pub-id-type="pmid">38407308</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkae105</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Ku acts in a unique way at the mammalian telomere to prevent end joining</article-title><source>Genes Dev</source><year>2000</year><volume>14</volume><fpage>2807</fpage><lpage>2812</lpage><pub-id pub-id-type="pmcid">PMC317061</pub-id><pub-id pub-id-type="pmid">11090128</pub-id><pub-id pub-id-type="doi">10.1101/gad.844000</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Connor</surname><given-names>MS</given-names></name><name><surname>Safari</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Songyang</surname><given-names>Z</given-names></name></person-group><article-title>The human Rap1 protein complex and modulation of telomere length</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>28585</fpage><lpage>28591</lpage><pub-id pub-id-type="pmid">15100233</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rai</surname><given-names>R</given-names></name><etal/></person-group><article-title>Homology directed telomere clustering, ultrabright telomere formation and nuclear envelope rupture in cells lacking TRF2(B) and RAP1</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><elocation-id>2144</elocation-id><pub-id pub-id-type="pmcid">PMC10104862</pub-id><pub-id pub-id-type="pmid">37059728</pub-id><pub-id pub-id-type="doi">10.1038/s41467-023-37761-w</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Jung</surname><given-names>D</given-names></name><name><surname>Jung</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>SG</given-names></name><name><surname>Lee</surname><given-names>I</given-names></name></person-group><article-title>Interaction of human Ku70 with TRF2</article-title><source>FEBS Lett</source><year>2000</year><volume>481</volume><fpage>81</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">10984620</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb</surname><given-names>TM</given-names></name><name><surname>Jackson</surname><given-names>SP</given-names></name></person-group><article-title>The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen</article-title><source>Cell</source><year>1993</year><volume>72</volume><fpage>131</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">8422676</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Oestreich</surname><given-names>S</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><article-title>Identification of human Rap1: implications for telomere evolution</article-title><source>Cell</source><year>2000</year><volume>101</volume><fpage>471</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">10850490</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A conserved motif within RAP1 has diversified roles in telomere protection and regulation in different organisms</article-title><source>Nat Struct Mol Biol</source><year>2011</year><volume>18</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="pmcid">PMC3688267</pub-id><pub-id pub-id-type="pmid">21217703</pub-id><pub-id pub-id-type="doi">10.1038/nsmb.1974</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costantini</surname><given-names>S</given-names></name><name><surname>Woodbine</surname><given-names>L</given-names></name><name><surname>Andreoli</surname><given-names>L</given-names></name><name><surname>Jeggo</surname><given-names>PA</given-names></name><name><surname>Vindigni</surname><given-names>A</given-names></name></person-group><article-title>Interaction of the Ku heterodimer with the DNA ligase IV/Xrcc4 complex and its regulation by DNA-PK</article-title><source>DNA Repair (Amst)</source><year>2007</year><volume>6</volume><fpage>712</fpage><lpage>722</lpage><pub-id pub-id-type="pmid">17241822</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Structural basis of long-range to short-range synaptic transition in NHEJ</article-title><source>Nature</source><year>2021</year><volume>593</volume><fpage>294</fpage><lpage>298</lpage><pub-id pub-id-type="pmcid">PMC8122075</pub-id><pub-id pub-id-type="pmid">33854234</pub-id><pub-id pub-id-type="doi">10.1038/s41586-021-03458-7</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Structure of an activated DNA-PK and its implications for NHEJ</article-title><source>Mol Cell</source><year>2021</year><volume>81</volume><fpage>801</fpage><lpage>810</lpage><elocation-id>e803</elocation-id><pub-id pub-id-type="pmcid">PMC7897279</pub-id><pub-id pub-id-type="pmid">33385326</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2020.12.015</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The three-dimensional structure of the C-terminal DNA-binding domain of human Ku70</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>38231</fpage><lpage>38236</lpage><pub-id pub-id-type="pmid">11457852</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kissinger</surname><given-names>CR</given-names></name><name><surname>Liu</surname><given-names>BS</given-names></name><name><surname>Martin-Blanco</surname><given-names>E</given-names></name><name><surname>Kornberg</surname><given-names>TB</given-names></name><name><surname>Pabo</surname><given-names>CO</given-names></name></person-group><article-title>Crystal structure of an engrailed homeodomain-DNA complex at 2.8 A resolution: a framework for understanding homeodomain-DNA interactions</article-title><source>Cell</source><year>1990</year><volume>63</volume><fpage>579</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">1977522</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Rap1 regulates TIP60 function during fate transition between two-cell-like and pluripotent states</article-title><source>Genes Dev</source><year>2022</year><volume>36</volume><fpage>313</fpage><lpage>330</lpage><pub-id pub-id-type="pmcid">PMC8973845</pub-id><pub-id pub-id-type="pmid">35210222</pub-id><pub-id pub-id-type="doi">10.1101/gad.349039.121</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanaoka</surname><given-names>S</given-names></name><etal/></person-group><article-title>NMR structure of the hRap1 Myb motif reveals a canonical three-helix bundle lacking the positive surface charge typical of Myb DNA-binding domains</article-title><source>J Mol Biol</source><year>2001</year><volume>312</volume><fpage>167</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">11545594</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schild-Poulter</surname><given-names>C</given-names></name><etal/></person-group><article-title>The binding of Ku antigen to homeodomain proteins promotes their phosphorylation by DNA-dependent protein kinase</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>16848</fpage><lpage>16856</lpage><pub-id pub-id-type="pmid">11279128</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Ly</surname><given-names>D</given-names></name><etal/></person-group><article-title>Telomere Loop Dynamics in Chromosome End Protection</article-title><source>Mol Cell</source><year>2018</year><volume>71</volume><fpage>510</fpage><lpage>525</lpage><elocation-id>e516</elocation-id><pub-id pub-id-type="pmid">30033372</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myler</surname><given-names>LR</given-names></name><etal/></person-group><article-title>The evolution of metazoan shelterin</article-title><source>Genes Dev</source><year>2021</year><volume>35</volume><fpage>1625</fpage><lpage>1641</lpage><pub-id pub-id-type="pmcid">PMC8653790</pub-id><pub-id pub-id-type="pmid">34764137</pub-id><pub-id pub-id-type="doi">10.1101/gad.348835.121</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez</surname><given-names>P</given-names></name><name><surname>Gómez-López</surname><given-names>G</given-names></name><name><surname>Pisano</surname><given-names>DG</given-names></name><name><surname>Flores</surname><given-names>JM</given-names></name><name><surname>Blasco</surname><given-names>MA</given-names></name></person-group><article-title>A genetic interaction between RAP1 and telomerase reveals an unanticipated role for RAP1 in telomere maintenance</article-title><source>Aging Cell</source><year>2016</year><volume>15</volume><fpage>1113</fpage><lpage>1125</lpage><pub-id pub-id-type="pmcid">PMC5114719</pub-id><pub-id pub-id-type="pmid">27586969</pub-id><pub-id pub-id-type="doi">10.1111/acel.12517</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rees</surname><given-names>DM</given-names></name><name><surname>Willhoft</surname><given-names>O</given-names></name><name><surname>Lin</surname><given-names>CL</given-names></name><name><surname>Bythell-Douglas</surname><given-names>R</given-names></name><name><surname>Wigley</surname><given-names>DB</given-names></name></person-group><article-title>Production and Assay of Recombinant Multisubunit Chromatin Remodeling Complexes</article-title><source>Methods Enzymol</source><year>2017</year><volume>592</volume><fpage>27</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">28668124</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punjani</surname><given-names>A</given-names></name><name><surname>Rubinstein</surname><given-names>JL</given-names></name><name><surname>Fleet</surname><given-names>DJ</given-names></name><name><surname>Brubaker</surname><given-names>MA</given-names></name></person-group><article-title>cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination</article-title><source>Nat Methods</source><year>2017</year><volume>14</volume><fpage>290</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">28165473</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liebschner</surname><given-names>D</given-names></name><etal/></person-group><article-title>Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix</article-title><source>Acta Crystallogr D Struct Biol</source><year>2019</year><volume>75</volume><fpage>861</fpage><lpage>877</lpage><pub-id pub-id-type="pmcid">PMC6778852</pub-id><pub-id pub-id-type="pmid">31588918</pub-id><pub-id pub-id-type="doi">10.1107/S2059798319011471</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Lohkamp</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>WG</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><article-title>Features and development of Coot</article-title><source>Acta Crystallogr D Biol Crystallogr</source><year>2010</year><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="pmcid">PMC2852313</pub-id><pub-id pub-id-type="pmid">20383002</pub-id><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goddard</surname><given-names>TD</given-names></name><etal/></person-group><article-title>UCSF ChimeraX: Meeting modern challenges in visualization and analysis</article-title><source>Protein Sci</source><year>2018</year><volume>27</volume><fpage>14</fpage><lpage>25</lpage><pub-id pub-id-type="pmcid">PMC5734306</pub-id><pub-id pub-id-type="pmid">28710774</pub-id><pub-id pub-id-type="doi">10.1002/pro.3235</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kidmose</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Namdinator - automatic molecular dynamics flexible fitting of structural models into cryo-EM and crystallography experimental maps</article-title><source>IUCrJ</source><year>2019</year><volume>6</volume><fpage>526</fpage><lpage>531</lpage><pub-id pub-id-type="pmcid">PMC6608625</pub-id><pub-id pub-id-type="pmid">31316797</pub-id><pub-id pub-id-type="doi">10.1107/S2052252519007619</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afonine</surname><given-names>PV</given-names></name><etal/></person-group><article-title>Real-space refinement in PHENIX for cryo-EM and crystallography</article-title><source>Acta Crystallogr D Struct Biol</source><year>2018</year><volume>74</volume><fpage>531</fpage><lpage>544</lpage><pub-id pub-id-type="pmcid">PMC6096492</pub-id><pub-id pub-id-type="pmid">29872004</pub-id><pub-id pub-id-type="doi">10.1107/S2059798318006551</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>MolProbity: More and better reference data for improved all-atom structure validation</article-title><source>Protein Sci</source><year>2018</year><volume>27</volume><fpage>293</fpage><lpage>315</lpage><pub-id pub-id-type="pmcid">PMC5734394</pub-id><pub-id pub-id-type="pmid">29067766</pub-id><pub-id pub-id-type="doi">10.1002/pro.3330</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jehl</surname><given-names>P</given-names></name><name><surname>Manguy</surname><given-names>J</given-names></name><name><surname>Shields</surname><given-names>DC</given-names></name><name><surname>Higgins</surname><given-names>DG</given-names></name><name><surname>Davey</surname><given-names>NE</given-names></name></person-group><article-title>ProViz-a web-based visualization tool to investigate the functional and evolutionary features of protein sequences</article-title><source>Nucleic Acids Res</source><year>2016</year><volume>44</volume><fpage>W11</fpage><lpage>15</lpage><pub-id pub-id-type="pmcid">PMC4987877</pub-id><pub-id pub-id-type="pmid">27085803</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkw265</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hégarat</surname><given-names>N</given-names></name><etal/></person-group><article-title>Cyclin A triggers Mitosis either via the Greatwall kinase pathway or Cyclin B</article-title><source>EMBO J</source><year>2020</year><volume>39</volume><elocation-id>e104419</elocation-id><pub-id pub-id-type="pmcid">PMC7265243</pub-id><pub-id pub-id-type="pmid">32350921</pub-id><pub-id pub-id-type="doi">10.15252/embj.2020104419</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>TW</given-names></name><name><surname>le Sage</surname><given-names>C</given-names></name><name><surname>Larrieu</surname><given-names>D</given-names></name><name><surname>Demir</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>SP</given-names></name></person-group><article-title>CRISPR-Cas9(D10A) nickase-based genotypic and phenotypic screening to enhance genome editing</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><elocation-id>24356</elocation-id><pub-id pub-id-type="pmcid">PMC4832145</pub-id><pub-id pub-id-type="pmid">27079678</pub-id><pub-id pub-id-type="doi">10.1038/srep24356</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vorhauser</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cell cycle-dependent S-sulfenyl proteomics uncover a redox switch in p21-CDK feedback governing the proliferation-senescence decision</article-title><source>bioRxiv</source><year>2024</year><elocation-id>2024.2009.2014.613007</elocation-id><pub-id pub-id-type="doi">10.1101/2024.09.14.613007</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agudelo</surname><given-names>D</given-names></name><etal/></person-group><article-title>Marker-free coselection for CRISPR-driven genome editing in human cells</article-title><source>Nat Methods</source><year>2017</year><volume>14</volume><fpage>615</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">28417998</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>GB</given-names></name><name><surname>Denchi</surname><given-names>EL</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><article-title>Ku70 stimulates fusion of dysfunctional telomeres yet protects chromosome ends from homologous recombination</article-title><source>Nat Cell Biol</source><year>2006</year><volume>8</volume><fpage>885</fpage><lpage>890</lpage><pub-id pub-id-type="pmid">16845382</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Riverol</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences</article-title><source>Nucleic Acids Res</source><year>2022</year><volume>50</volume><fpage>D543</fpage><lpage>D552</lpage><pub-id pub-id-type="pmcid">PMC8728295</pub-id><pub-id pub-id-type="pmid">34723319</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkab1038</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>RAP1 and APOLLO redundantly prevent cNHEJ at telomeres in mouse and human cells.</title><p><bold>a</bold>. Representative FISH of metaphase spreads of ApolloF/F Lig4+/+ MEFs 108 h after transduction with sgRap1 and/or Hit &amp; Run Cre. Telomeres were detected with Cy3-(TTAGGG)3 (green). DNA was stained with DAPI (magenta). White and green arrows highlight chromatid- and chromosome type fusions respectively. See also <xref ref-type="supplementary-material" rid="SD1">figure S1a</xref> <bold>b-c</bold>. Quantification of the percentage of telomeres involved in chromatid (b) or chromosome (c) fusions per metaphases after removal of Apollo and/or RAP1 as indicated in the presence or absence of LIG4. Data from 3 independent experiments, 10 metaphases per experiment (n = 30 total), with median.<bold>d</bold>. Representative FISH as in (a) but with metaphase spreads from p53-/- RAP1+/+ or p53-/- RAP1-/- RPE-1 cells as indicated 120 h after transduction with Cas9 and control or Apollo-targeting sgRNA as indicated. <bold>e</bold>. Quantification of the percentage of telomeres fused per metaphases after removal of Apollo as described in (d). Data from 3 independent experiments, 10 metaphases per experiment (n = 30 total), with median. See also, <xref ref-type="supplementary-material" rid="SD1">figure S1</xref>. All statistics by ordinary One-way ANOVA. ‘ns’ not significant, **P ≤ 0.01 ***P ≤ 0.001 ****P ≤ 0.0001.</p></caption><graphic xlink:href="EMS202434-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>TRF2, RAP1 and DNA-PK form a terminal complex at telomeric DNA ends.</title><p><bold>a</bold>. Outline of DNaseI footprinting experiment. 32P-labelled 5’ end highlighted by a red asterisk. Radiolabelled template is incubated with KU and DNA-PKcs prior to the addition of Shelterin composed of TRF1, TRF2, RAP1, TIN2, POT1 and TPP1. DNase I digested products are then analysed by denaturing Urea-PAGE <bold>b-f</bold>. DNase I footprinting of telomere end-binding complexes. Proteins omitted as indicated. Nucleotides from the 5’ telomeric end indicated.</p></caption><graphic xlink:href="EMS202434-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Three distinct interfaces are required for the complex with DNA-PK.</title><p><bold>a</bold>. domain organisation of RAP1 and TRF2. <bold>b-d</bold>. DNaseI footprinting of telomere end-binding complexes. Proteins omitted as indicated. See <xref ref-type="supplementary-material" rid="SD1">figure S1</xref> for mutant details. <bold>e</bold>. protein cross-linking analysis of RAP1 and KU in the presence of DNA. Proteins were mixed with crosslinker and the products of the reaction were separated on a denaturing tris-acetate polyacrylamide gel and analysed by silver staining or immunoblotting as indicated. Arrowheads mark the position of crosslinked species containing only KU, or KU and RAP1 as indicated. Bottom and top bands observed with KU alone are presumed to represent KU dimers and tetramers respectively <bold>f and g</bold>. as in b.</p></caption><graphic xlink:href="EMS202434-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Cryo-EM structure of the RAP1:DNA-PK complex.</title><p><bold>a</bold>. Composite electron density map with protein domains coloured as indicated. Schematic shows proteins used for structure determination. Hatching indicates domains not visualised <bold>b</bold>. Subsection of the structure in a, showing the KU70 SAP and RAP1 myb domains bound to DNA. <bold>c, d</bold>. The RAP1 BRCT domain pictured bound to the KU70 vWA domain, highlighting RAP1 and KU residues that mediate the interaction. <bold>e-g</bold>. DNase I footprinting analysis of telomere end-binding complexes with the proteins indicated. RAP1 KR/DE contains mutations K39D, R40E and R55E. KU DE/KR contains mutations KU70 D496K, E499R and KU80 D327K h. RAP1 BRCT KU cryo-EM model overlayed with the LIG4 BRCT domain from cryo-EM structure PDB-7It3</p></caption><graphic xlink:href="EMS202434-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>TRF2 and RAP1 prevent cNHEJ at telomeres by blocking XRCC4/LIG4 recruitment to DNA-PK</title><p><bold>a</bold>. Outline of the KU pulldown approach. See <xref ref-type="sec" rid="S1">methods</xref> for details <bold>b-d</bold>. KU-bound proteins from reactions containing KU70/80, DNA-PKcs, XRCC4/LIG4, TRF2, RAP1 and template DNA unless indicated were separated by SDS-PAGE and immunoblotted as indicated. TRF2, RAP1 and LIG4 detected with anti-strep tag antibody, KU70 with anti-FLAG antibody. As shown in (b), associated of TRF2 with KU is mediated by template DNA <bold>e</bold>. Quantification of the percentage of telomeres involved in chromosome fusions per metaphases upon over-expression of mouse RAP1, RAP1 KR/DE and RAP1 R130E after Crispr- and Cre-mediated deletion of Rap1 and Apollo respectively in ApolloF/F Lig4+/+ MEFs. Data from 3 independent experiments, 10 metaphases per experiment (n = 30 total), with median. Statistics by ordinary One-way ANOVA. See <xref ref-type="supplementary-material" rid="SD1">Fig. S8</xref> for further details. <bold>f</bold>. Quantification of the percentage of telomeres fused per metaphase upon Crispr-mediated deletion of Apollo in p53−/− RPE-1 cells with wildtype RAP1 or the RAP1 KR/DE mutant. Data from 3 independent experiments, 10 metaphases per experiment (n = 30 total), with median. Statistics as in (e). See <xref ref-type="supplementary-material" rid="SD1">Fig. S8</xref> for further details <bold>g</bold>. Model for the direct inhibition of DNA-PK by RAP1 at mammalian telomeres. When assembled on telomeric DNA, DNA-PK is bound by the RAP1 myb and BRCT domains, which acts as a circuit breaker that prevents DNA-PK from engaging LIG4.</p></caption><graphic xlink:href="EMS202434-f005"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Oligonucleotides used</title></caption><table frame="box" rules="all"><tbody><tr><td valign="top" align="left" style="border-top: 1px solid #000000;border-bottom: 1px solid #000000;border-right: 1px solid #000000;border-left: 1px solid #000000">PE1</td><td valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-bottom: 1px solid #000000">CGGTACCCGGGGATCCTCTAGAGTCGACGAAGACTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGG</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">PE2</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">CGGTACCCGGGGATCCTCTAGAGTCGACGAAGACCACCAGCTAGTACAACCACATACTTTATGGAGAAATTTCAAAACGCAAAGAAGAACGAAGATAAACAAATTGCCAAGTTTGAAAGCATGATGAATGCAAGAGTACATACGTTCAGTACCGATGAGAAGAAATATGTGCCGATAATCACAAACGAATTAGAAAGCTTTTCAAATCTTTGGGTTAAAAAGAGGTACATACCTGAAGATGACTTAAAACGGGCTTTGCATGAGATCAAAATCCTTCGGTTGGGCAAACTTTTTGCTAAAATTCGCCCACCTAAATTTCAAGAGCCTGAATACGCCAACTGGGCCACCGTAGGCCTCATTAGCCACAAATCGGACATCAAATTTAC</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">PE3</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Biotin-CGTCTATATTCTATTGTCTCTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAACATCAGTCTCACATAGATTAGCTCACGC</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">PE4</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">GCGTGAGCTAATCTATGTGAGACTGATGTTAACCCTAACCCTAACCCTAACCCTAACCCTAACCCTAACCCTAACCCTAAGAGACAATAGAATATAGACG</td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Constructs used</title></caption><table frame="box" rules="all"><thead><tr><th valign="top" align="left" style="border: 1px solid #000000;background: #b0b3b2">Insert in pACEBAC1 vector</th><th valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-bottom: 1px solid #000000;background: #b0b3b2">UniProt ID</th><th valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-bottom: 1px solid #000000;background: #b0b3b2">Tag</th><th valign="top" align="left" style="border-top: 1px solid #000000;border-right: 1px solid #000000;border-bottom: 1px solid #000000;background: #b0b3b2">Mutation</th></tr></thead><tbody><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">KU70/80</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">P12956, XRCC6_HUMAN<break/>P13010, XRCC5_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">FLAG, Ku70 N-terminal</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">WT</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">KU70/80 DE/KR</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">P12956, XRCC6_HUMAN<break/>P13010, XRCC5_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">FLAG, Ku70 N-terminal</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">KU70 D327K + KU80 D496K, E499R point mutations</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">RAP1</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Q9NYB0, TE2IP_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Dual Strep, N-terminal</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">WT</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">RAP1 BRCTpm</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Q9NYB0, TE2IP_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Dual Strep, N-terminal</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">K39D, R40E, R55E point mutations</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">RAP1 ΔBRCT</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Q9NYB0, TE2IP_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Dual Strep, N-terminal</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">M1-D108 deletion</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">RAP1 Δmyb</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Q9NYB0, TE2IP_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Dual Strep, N-terminal</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Q128-D199 deletion</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">RAP1 ΔRCT</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Q9NYB0, TE2IP_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Dual Strep, N-terminal</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">S291-K399 deletion</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">RAP1 ΔC</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Q9NYB0, TE2IP_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Dual Strep, N-terminal</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">E224-K399 deletion</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">Teb1:RAP1</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Q10274, TEB1_SCHPO Q9NYB0, TE2IP_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Dual Strep, N-terminal</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Teb1 22-227 fused to RAP1 1-399, with intervening sequence GGSGGLEVLFQ GPGGSGG</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">LIG4:RAP1 ΔBRCT</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">P49917, DNLI4_HUMAN<break/>Q9NYB0, TE2IP_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Dual Strep, N-terminal</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Ligase IV 656-785 fused to RAP1 109-399</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">TRF2</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Q15554, TERF2_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Dual Strep, N-terminal</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">WT</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">TRF2 RBM</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Q15554, TERF2_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Dual Strep, N-terminal</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">L330R point mutation</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">TRF2 Δbasic</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Q15554, TERF2_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Dual Strep, N-terminal</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">M1-G86 deletion</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">TRF2 Δmyb</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Q15554, TERF2_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Dual Strep, N-terminal</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">T483-N542 deletion</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">TRF2 Δmyb Δbasic</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Q15554, TERF2_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Dual Strep, N-terminal</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">M1-G86, T483-N542 deletions</td></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">shelterin:<break/>TRF1<break/>TRF2<break/>RAP1<break/>TPP1<break/>POT1<break/>TIN2</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">P54274, TERF1_HUMAN<break/>Q15554, TERF2_HUMAN<break/>Q9NYB0, TE2IP_HUMAN<break/>Q96AP0, ACD_HUMAN<break/>Q9NUX5, POTE1_HUMAN<break/>Q9BSI4, TINF2_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Strep, N-terminal on TINF2</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000"/></tr><tr><td valign="top" align="left" style="border-right: 1px solid #000000;border-bottom: 1px solid #000000;border-left: 1px solid #000000">XRCC4/LIG4</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Q13426, XRCC4_HUMAN<break/>P49917, DNLIG4_HUMAN</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000">Dual Strep, C-terminal on LIG4</td><td valign="top" align="left" style="border-bottom: 1px solid #000000;border-right: 1px solid #000000"/></tr></tbody></table></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Cryo-EM parameters</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" style="border-top: 2px solid #008000;border-bottom: 1.5px solid #008000"/><th valign="top" align="left" style="border-top: 2px solid #008000;border-bottom: 1.5px solid #008000">Full end-binding complex</th><th valign="top" align="left" style="border-top: 2px solid #008000;border-bottom: 1.5px solid #008000">KU:RAP1 local refinement</th><th valign="top" align="left" style="border-top: 2px solid #008000;border-bottom: 1.5px solid #008000">DNA-PKcs local refinement</th></tr></thead><tbody><tr><td valign="top" align="left"><bold>Data collection and processing</bold></td><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/></tr><tr><td valign="top" align="left">Magnification</td><td valign="top" align="left">x150,000</td><td valign="top" align="left">x150,000</td><td valign="top" align="left">x150,000</td></tr><tr><td valign="top" align="left">Voltage (kV)</td><td valign="top" align="left">200</td><td valign="top" align="left">200</td><td valign="top" align="left">200</td></tr><tr><td valign="top" align="left">Electron exposure (e–/Å<sup>2</sup>)</td><td valign="top" align="left">50.0</td><td valign="top" align="left">50.0</td><td valign="top" align="left">50.0</td></tr><tr><td valign="top" align="left">Defocus range (μm)</td><td valign="top" align="left">-1.0 to -2.5</td><td valign="top" align="left">-1.0 to -2.5</td><td valign="top" align="left">-1.0 to -2.5</td></tr><tr><td valign="top" align="left">Pixel size (Å)</td><td valign="top" align="left">0.94</td><td valign="top" align="left">0.94</td><td valign="top" align="left">0.94</td></tr><tr><td valign="top" align="left">Symmetry imposed</td><td valign="top" align="left">C1</td><td valign="top" align="left">C1</td><td valign="top" align="left">C1</td></tr><tr><td valign="top" align="left">Initial particle images (no.)</td><td valign="top" align="left">7,463,361</td><td valign="top" align="left">7,463,361</td><td valign="top" align="left">7,463,361</td></tr><tr><td valign="top" align="left">Final particle images (no.)</td><td valign="top" align="left">526,885</td><td valign="top" align="left">526,885</td><td valign="top" align="left">370,172</td></tr><tr><td valign="top" align="left">Map resolution (Å)</td><td valign="top" align="left">3.58</td><td valign="top" align="left">3.32</td><td valign="top" align="left">3.40</td></tr><tr><td valign="top" align="left">    FSC threshold</td><td valign="top" align="left">0.143</td><td valign="top" align="left">0.143</td><td valign="top" align="left">0.143</td></tr><tr><td valign="top" align="left">Map resolution range (Å)</td><td valign="top" align="left">3.0-7.0</td><td valign="top" align="left">3.0-7.0</td><td valign="top" align="left">3.0-6.0</td></tr><tr><td valign="top" align="left"><bold>Refinement (from composite map, statistics from MolProbity)</bold></td><td valign="top" align="left">PDB 8RD4</td><td valign="top" align="left">PDB 8RD4</td><td valign="top" align="left">PDB 8RD4</td></tr><tr><td valign="top" align="left">Initial model used (PDB code)</td><td valign="top" align="left">7K1K, 1FEX, 1JJR</td><td valign="top" align="left">7K1K, 1FEX, 1JJR</td><td valign="top" align="left">7K1K, 1FEX, 1JJR</td></tr><tr><td valign="top" align="left">Model resolution (Å)</td><td valign="top" align="left">3.7</td><td valign="top" align="left">3.7</td><td valign="top" align="left">3.7</td></tr><tr><td valign="top" align="left">    FSC threshold</td><td valign="top" align="left">0.5</td><td valign="top" align="left">0.5</td><td valign="top" align="left">0.5</td></tr><tr><td valign="top" align="left">Model resolution range (Å)</td><td valign="top" align="left">2.9-4.0</td><td valign="top" align="left">2.9-4.0</td><td valign="top" align="left">2.9-4.0</td></tr><tr><td valign="top" align="left">Map sharpening <italic>B</italic> factor (Å<sup>2</sup>)</td><td valign="top" align="left">-70</td><td valign="top" align="left">-70</td><td valign="top" align="left">-70</td></tr><tr><td valign="top" align="left">Model composition</td><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/></tr><tr><td valign="top" align="left">    Non-hydrogen atoms</td><td valign="top" align="left">40,731</td><td valign="top" align="left">40,731</td><td valign="top" align="left">40,731</td></tr><tr><td valign="top" align="left">    Protein residues</td><td valign="top" align="left">4,868</td><td valign="top" align="left">4,868</td><td valign="top" align="left">4,868</td></tr><tr><td valign="top" align="left">    Ligands</td><td valign="top" align="left">0</td><td valign="top" align="left">0</td><td valign="top" align="left">0</td></tr><tr><td valign="top" align="left"><italic>B</italic> factors (Å<sup>2</sup>)</td><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/></tr><tr><td valign="top" align="left">    Protein</td><td valign="top" align="left">-75.75</td><td valign="top" align="left">-75.75</td><td valign="top" align="left">-75.75</td></tr><tr><td valign="top" align="left">    Ligand</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td><td valign="top" align="left">-</td></tr><tr><td valign="top" align="left">R.m.s. deviations</td><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/></tr><tr><td valign="top" align="left">    Bond lengths (Å)</td><td valign="top" align="left">0.004</td><td valign="top" align="left">0.004</td><td valign="top" align="left">0.004</td></tr><tr><td valign="top" align="left">    Bond angles (°)</td><td valign="top" align="left">0.711</td><td valign="top" align="left">0.711</td><td valign="top" align="left">0.711</td></tr><tr><td valign="top" align="left">Validation</td><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/></tr><tr><td valign="top" align="left">    MolProbity score</td><td valign="top" align="left">2.17</td><td valign="top" align="left">2.17</td><td valign="top" align="left">2.17</td></tr><tr><td valign="top" align="left">    Clashscore</td><td valign="top" align="left">12.66</td><td valign="top" align="left">12.66</td><td valign="top" align="left">12.66</td></tr><tr><td valign="top" align="left">    Poor rotamers (%)</td><td valign="top" align="left">0.46</td><td valign="top" align="left">0.46</td><td valign="top" align="left">0.46</td></tr><tr><td valign="top" align="left">Ramachandran plot</td><td valign="top" align="left"/><td valign="top" align="left"/><td valign="top" align="left"/></tr><tr><td valign="top" align="left">    Favored (%)</td><td valign="top" align="left">89.85</td><td valign="top" align="left">89.85</td><td valign="top" align="left">89.85</td></tr><tr><td valign="top" align="left">    Allowed (%)</td><td valign="top" align="left">10.13</td><td valign="top" align="left">10.13</td><td valign="top" align="left">10.13</td></tr><tr><td valign="top" align="left" style="border-bottom: 2px solid #008000">    Disallowed (%)</td><td valign="top" align="left" style="border-bottom: 2px solid #008000">0.02</td><td valign="top" align="left" style="border-bottom: 2px solid #008000">0.02</td><td valign="top" align="left" style="border-bottom: 2px solid #008000">0.02</td></tr></tbody></table></table-wrap></floats-group></article>